Perkins Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$74M Buy
2,281,213
+332,227
+17% +$10.5M 0.92% 39
2016
Q4
$60.1M Buy
1,948,986
+391,153
+25% +$11.9M 0.77% 46
2016
Q3
$50.1M Sell
1,557,833
-8,292
-0.5% -$277K 0.69% 57
2016
Q2
$52.3M Buy
1,566,125
+4,112
+0.3% +$131K 0.79% 50
2016
Q1
$43.9M Buy
1,562,013
+439,138
+39% +$12.5M 0.66% 60
2015
Q4
$34.4M Sell
1,122,875
-105,372
-9% -$3.31M 0.5% 74
2015
Q3
$36.6M Sell
1,228,247
-20,557
-2% -$659K 0.53% 70
2015
Q2
$39.7M Sell
1,248,804
-45,184
-3% -$1.47M 0.45% 87
2015
Q1
$42.7M Buy
1,293,988
+147,813
+13% +$4.7M 0.43% 84
2014
Q4
$33.9M Buy
1,146,175
+270,991
+31% +$7.77M 0.32% 100
2014
Q3
$24.6M Buy
875,184
+15,179
+2% +$426K 0.22% 118
2014
Q2
$24.2M Buy
860,005
+6,266
+0.7% +$179K 0.2% 125
2014
Q1
$26M Buy
853,739
+109,851
+15% +$3.28M 0.2% 125
2013
Q4
$21.6M Sell
743,888
-45,075
-6% -$1.31M 0.15% 146
2013
Q3
$21.5M Buy
788,963
+5,312
+0.7% +$145K 0.15% 146
2013
Q2
$20.8M Buy
+783,651
New +$21.7M 0.14% 158

Other funds holding PFE

Perkins Investment Management's PFE Position: Q1 2017 in Review

Perkins Investment Management increased its Pfizer (PFE) stake by 17% in Q1 2017, buying an estimated $10.5M and bringing the position to 2,281,213 shares worth $74M. The position accounts for 0.92% of the portfolio, ranked #39.

Perkins Investment Management first reported a position in PFE in Q2 2013 and has held it in 16 quarters since. 2,075 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

  • Perkins Investment Management held 2,281,213 shares of Pfizer worth $74M as of Q1 2017.
  • Perkins Investment Management bought 332,227 Pfizer shares in Q1 2017, an estimated $10.5M.
  • Pfizer made up 0.92% of Perkins Investment Management's portfolio in Q1 2017, its #39 holding.
  • Perkins Investment Management first reported a position in Pfizer in Q2 2013 and has held it in 16 quarters since.
  • 2,075 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Perkins Investment Management's 13F filing for Q1 2017, filed 15 May 2017.